Type 2 diabetes mellitus is a metabolic disorder characterized by hyperglycemia and is
especially prevalent in the elderly. Because aging is a risk factor for type 2 diabetes mellitus …

Neuronal Ca2+ dyshomeostasis associated with cognitive impairment and mediated by
changes in several Ca2+ sources has been seen in animal models of both aging and …

Diabetes and Alzheimer's disease share pathologic links toward cognitive deficits.
Pharmacologic agonist of the nuclear receptor, peroxisomal proliferator-activating receptor …

Metformin (Met) is a first-line drug for type 2 diabetes mellitus (T2DM). Numerous studies
have shown that Met exerts beneficial effects on a variety of neurological disorders …

Recently it has become clear that conditions of insulin resistance/metabolic syndrome,
obesity and diabetes, are linked with moderate cognitive impairment in normal aging and …

Aim We examined if tonic γ‐aminobutyric acid (GABA)‐activated currents in primary
hippocampal neurons were modulated by insulin in wild‐type and tg‐APPSwe mice, an …

Pioglitazone (PIO) is a peroxisome proliferator-activated receptor-γ (PPARγ) agonist in
clinical use for treatment of type 2 diabetes (T2DM). Accumulating evidence suggests …

INTRODUCTION: Pioglitazone, a peroxisome proliferator activated receptor γ (PPARγ)
agonist, is widely used in clinical medicine as a treatment for type 2 diabetes and is recently …

As an antidiabetic agent, rosiglitazone (ROSI) binds and activates peroxisome proliferator-
activator receptor gamma (PPARγ), altering the expression of genes involved in glucose …

Aims: Pioglitazone, known as a peroxisome proliferator‐activated receptor γ (PPARγ)
agonist, is used to treat type 2 diabetes mellitus (T2DM). T2DM has been associated with …